Portopulmonary Hypertension
8
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
38%
3 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Heart Problems in Children With Chronic Liver Disease
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Revatio Portal-Pulmonary Arterial Hypertension Trial
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
Ambrisentan for Treatment of Portopulmonary Hypertension